Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study

BACKGROUND AND OBJECTIVES: Empagliflozin, a sodium glucose cotransporter-2 inhibitor, was recently evaluated in a randomized, controlled trial (RCT) in drug-naïve Type 2 diabetes mellitus (T2DM) patients managed on diet and exercise therapy. Efficacy and safety of empagliflozin in Indian subgroup of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Sunil, Shaikh, Shehla, Joshi, Pooja, Bhure, Shraddha, Suvarna, Viraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367232/
https://www.ncbi.nlm.nih.gov/pubmed/28459027
http://dx.doi.org/10.4103/ijem.IJEM_517_16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367232/
https://www.ncbi.nlm.nih.gov/pubmed/28459027
http://dx.doi.org/10.4103/ijem.IJEM_517_16

Ejemplares similares